ClinTec Sees Rise in Revenues and Growth in the Middle East
ClinTec, a full service multinational contract research organisation (CRO), has today announced that it has achieved organic growth with a 45 per cent increase in global sales revenues over the last twelve months; expanded its client base and signing new contracts with 11 of the world’s top 25 pharmaceutical firms.
With a presence in some 40 countries around the world, ClinTec International manages clinical trials in all major therapeutic areas, including oncology, neurology, cardiovascular, respiratory as well as gastroenterology.
Dr. Rabinder Buttar, the company’s founder, President and CEO commented: “The launch of our Cairo office in October was one of the high points of the year. Apart from providing our global pharmaceutical associates with access to new patient populations, ClinTec Cairo cements our reputation as the major CRO in the Middle East and North Africa (MENA) region."
ClinTec has played a key role in 2009 in facilitating complex restructuring programmes for Global Pharma, who are searching for innovative ways to optimise their R&D efforts. The shift of research delivery from West to East is an area in which ClinTec is able to offer a credible solution for using a blend between flexible resource solutions and off-shore project delivery.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
